Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.47 |
| ▸ | PPARA | Q07869 | 11/20 | 0.47 |
| ▸ | PPARD | Q03181 | 6/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.40 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752656 | 0.90 | PPARG (0.58) | PPARGPPARAPPARDPTGDR2 | |
| SCHEMBL6752363 | 0.89 | PPARA (0.54) | PPARGPPARAPPARD | |
| SCHEMBL6752687 | 0.87 | PPARA (0.48) | PPARGPPARAPPARD | |
| SCHEMBL6748817 | 0.87 | PPARG (0.57) | PPARGPPARAPPARDPTGDR2 | |
| SCHEMBL6752859 | 0.86 | PPARG (0.46) | PPARGPPARAPPARDHDAC1HDAC11 | |
| SCHEMBL6752369 | 0.85 | PPARG (0.46) | PPARGPPARAPPARDSRRPSAT1 | |
| SCHEMBL7518145 | 0.84 | PPARA (0.53) | PPARGPPARAPPARDPTGDR2 | |
| SCHEMBL7514598 | 0.80 | ENPP2 (0.53) | PTGDR2HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL6752674 | 0.80 | PPARA (0.65) | PPARGPPARAPPARD | |
| SCHEMBL7530431 | 0.80 | PPARG (0.51) | PPARGPPARAPPARDSRRPSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703401-B2 | USEFUL IN THE TREATMENT AND/OR PREVENTION OF CONDITIONS MEDIATED BY CLEAR RECEPTORS, IN PARTICULAR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR). | NOVO NORDISK A/S (DK) | 2004-03-09 | — | — | US | claimed |
| US-20020065268-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-30 | — | — | US | claimed |
| US-20020065267-A1 | Compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-30 | — | — | US | claimed |
| US-20020061880-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-23 | — | — | US | claimed |
| US-20020061876-A1 | Compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-23 | — | — | US | claimed |
| US-20020055502-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-09 | — | — | US | claimed |
| US-6703401-B2 | USEFUL IN THE TREATMENT AND/OR PREVENTION OF CONDITIONS MEDIATED BY CLEAR RECEPTORS, IN PARTICULAR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR). | NOVO NORDISK A/S (DK) | 2004-03-09 | — | — | US | disclosed |
| US-20020065268-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-30 | — | — | US | disclosed |
| US-20020065267-A1 | Compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-30 | — | — | US | disclosed |
| US-20020061880-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-23 | — | — | US | disclosed |
| US-20020061876-A1 | Compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-23 | — | — | US | disclosed |
| US-20020055502-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-09 | — | — | US | disclosed |
| US-6365586-B1 | REDUCE BLOOD GLUCOSE AND TRIGLYCERIDE LEVELS AND ARE USEFUL FOR THERAPY OF AILMENTS AND DISORDERS SUCH AS DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061880-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20020065267-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20020061876-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20020055502-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20020065268-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.